News of Eli Lilly and Co. purchasing Ventyx Biosciences Inc. for $14 per share arrived after market close Jan. 7, following unconfirmed rumors of the buyout that drove shares up by more than 52% at one point.
Regulatory snapshots, including global drug submissions and approvals, and other regulatory decisions and designations: Alkermes, Ark, Bioarctic, Biogen, Biosplice, Cellenkos, Eisai, GSK, Johnson & Johnson, Milestone, Oculis, Zai Lab.
Biopharma happenings, including deals and partnerships, and other news in brief: Astrazeneca, Boehringer Ingelheim, Bostongene, Cartography, Convergent, Day One, Galapagos, Gasherbrum, Genentech, Gilead, Factor, Immuneonco, Instil, Lineage Cell, Mersana, Northstar Medical Radioisotopes, Onconano, Pfizer, Variant.
South Korea will implement a new regulation on synthetic biology in April 2026, aiming to foster innovations across both biotechnology and biomanufacturing.
Confirmed news of Eli Lilly and Co. purchasing Ventyx Biosciences Inc. for $14 per share arrived within a day of swirling rumors that drove shares of the San Diego-based biopharma company up by more than 52% at one point on Jan. 7.
As widely expected, GSK plc and Ionis Pharmaceuticals Inc. reported positive findings from two pivotal trials testing bepirovirsen in chronic hepatitis B, showing the antisense oligonucleotide therapy achieved a statistically and clinically meaningful functional cure rate, indicating a potential transition in CHB treatment beyond the current viral suppression-focused standard of care.
RSS
